Clinical Trials Logo

BRAF V600E Mutation Present clinical trials

View clinical trials related to BRAF V600E Mutation Present.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04061980 Recruiting - Clinical trials for Metastatic Thyroid Gland Carcinoma

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Start date: October 30, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well encorafenib and binimetinib given with or without nivolumab works in treating patients with BRAF V600 mutation positive thyroid cancer that has spread to other places in the body (metastatic) and does not respond to radioiodine treatment (refractory). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The trial aims to find out if the combination of encorafenib and binimetinib, with and without study nivolumab, is a safe and effective way to treat metastatic radioiodine refractory thyroid cancer.

NCT ID: NCT03224767 Recruiting - Clinical trials for BRAF V600E Mutation Present

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Start date: August 4, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.